Background
Radon—a natural radioactive gas originating from the decay series of uranium found in the Earth’s crust—accounts for a significant proportion of the annual effective dose of natural radioactivity [
1], and have been extensively studied in relation lung cancer [
2]. Radon is fat-soluble, tends to bio-accumulate in tissues with higher fat content such as the breast, has a relatively short half-life (~ 3.8 days), and undergoes rapid decay processes to emit alpha particles that may interact with biological tissues and macro-molecules [
3,
4]. Similar to other ionizing radiation, radon and its decay products are mutagenic [
4], as they could lead to single and double-strand DNA breaks [
5], pyrimidine dimer formations [
6], intra- and inter-chromosomal aberrations [
7,
8] sister chromatid exchange [
9,
10] micronuclei formation [
11] and eventually genomic instability [
5]. Residential radon exposures were associated with increased lung cancer risk among never smokers who carried genetic polymorphisms in DNA-repair genes [
12]. Chromosomal abnormality was also observed in lung cancer patients exposure to radon and air pollution [
13]. In areas with high radon background, increased levels of indoor radon concentrations were associated with chromosomal translocation and aberrations [
14,
15]. Although limited by the number of cases, a suggestive association was observed between residential radon and higher risk of breast cancer, in a radon-prone area [
16]. In the Nurses’ Health Study II (NHSII), VoPham et al. conducted a prospective analysis of radon exposure and incidence of invasive breast cancer, and demonstrated that cumulative radon exposure, even at low doses, was associated with higher risk of estrogen receptor (ER)-negative breast cancer [
17]. However, the molecular mechanisms underlying the effects of radon on breast cancer risk are not fully understood. A better understanding of the biological pathways associated with low dose radon in population-based studies may provide important human evidence supporting the role of environmental exposure in breast carcinogenesis.
The study of transcriptome-wide gene expression profiling in breast tumor and normal-adjacent tissue offers a unique opportunity to uncover biological mechanisms linking environmental exposures such as radon and breast cancer risk. The breast tissue-specific transcriptome provides deep coverage of measurable mRNA transcripts, and provides a quantitative and systematic readout of the pathophysiological status of breast tissue that reflects the complex interplay between genetics and both endogenous and exogenous environmental influences. In breast cancer cell lines, ionizing radiation leads to differential gene expression in pathways related to apoptosis [
18,
19] inflammation [
19] oxidative stress [
19,
20] DNA damage and repair [
12,
19] and cell cycle regulation [
19]. As tissue specific transcriptomes capture detailed levels of molecular activities, transcriptomic analyses of breast tumor and normal-adjacent tissues may provide a comprehensive assessment of biological mechanisms underlying radon related carcinogenesis.
In two large-scale prospective cohort studies in the United States, we investigated the association between radon concentrations at the participants’ addresses—estimated as cumulative averages up to the year of breast cancer diagnosis—and transcriptome-wide gene expression in breast tumor and normal-adjacent tissues. We hypothesized that breast cancer cases living in areas of higher radon concentration would have differential gene expression patterns in tumor and normal-adjacent tissues compared with women living in areas of lower concentrations. While differences in gene expression signatures in tumor tissues may provide information about radon-associated tumor initiation and progression; alterations in gene expression patterns in normal-adjacent tissues may reflect a larger field effect in the breast before carcinogenesis.
Discussion
To the best of our knowledge, this is the first prospective population-based study investigating the association between low dose radon exposure and gene expression patterns in FFPE breast tumor blocks obtained from invasive breast cancer cases. Overall, we did not see strong evidence of radon exposure being differentially associated with any single gene. However, pathway analyses identified two gene sets (P38MAPK signaling and phosphocholine synthesis) that were significantly enriched after multiple testing adjustment. As we still observed biological effects when radon was modelled at a cutoff (2pCi) below the EPA recommendations (4pCi), this suggests that radon could still possess adverse health consequences at a concentration below the current recommendations.
Radon was among the first human environmental carcinogens identified and was originally described as the chemical associated with “the wasting disease of miners” by Paracelsus in 1567 [
39]. To date, it is widely accepted that radon and its progeny contribute significantly to excess lung cancer among underground miners [
40,
41]. Although not nearly comparable to the high dose received by uranium miners, several case-control studies conducted in non-occupational settings showed that low dose radon exposure was associated with higher risk of lung cancer [
42‐
46]. In fact, the National Council on Radiation Protection & Measurements (NCRP) estimated approximately 10,000 deaths per year in the U.S., for an average annual radon exposure of 1 pCi/L [
40,
47]. Since inhalation is the primary route of exposure, much of the current research for radon focuses on lung cancer as the main health outcome. Nevertheless, based on its lipophilic properties, biokinetic models estimated that deliverable concentrations of radon decay products were detected in the breast and lung at an annual dose of 1000 Bq/L (or 2.7 × 10
4 pCi/L) [
3]. In the NHSII, we previously observed that cumulative radon exposure, even at low doses, was associated with higher risk of ER-negative breast cancer [
17]. Consistent with our previous findings, the current work identified mitogenic (P38MAPK signaling: up-regulated) and phosphocholine (synthesis of phosphocholine: down-regulated) pathways that were significantly enriched in ER-negative breast tumor and normal-adjacent tissues (FDR < 25%).
Previous experimental studies have shown that MAPK signaling and phosphocholine biosynthesis played key roles in ionizing radiation induced tumorigenesis. In normal human diploid and tumor cell lines, low dose ionizing radiation could stimulate the MAPK pathway and enhance cell proliferation [
48]. Exposure to moderate-to-low dose ionizing radiation also led to the activation of the p42/44 MAPK pathway in animal models [
49]. In mammalian cell lines, p38 MAPK has been shown to govern the G2-M transition, and activation of p38 MAPK cascade is required for ionizing radiation induced G2 arrest [
50]. Ionizing radiation could also destruct cellular membranes, hydrolyze sphingomyelin to generate phosphocholine, and initiate programmed cell death [
51]. In population-based studies, pre-diagnostic phosphocholine has also been shown to be a reproducible biomarker for breast cancer prognosis in multiple cohort studies [
52‐
54].
Single gene analyses identified
PLCH2, a member of the phospholipase C super family, to be associated with radon exposures in ER-positive normal-adjacent samples.
PLCH2 has essential role for the cleavage of membrane phospholipids, thereby generating second messengers inositol 1,4,5-trisphosphate (PtdIns(4,5)P2) and 1,2-diacylglycerol (DAG) [
55,
56]. The 2 s messengers re important for G protein coupled receptor activation. The suppression of
PLCH2 in ER-positive normal adjacent tissue may represents an adaptive/maladaptive response to radon exposures. Stratified analysis by smoking status (never smokers, women who smoked ≤16 pack-years and women who smoked > 16 pack-years) yielded comparable magnitudes of effect estimates, indicating that the association between radon and
PLCH2 did not differ by smoking status. Radon is ionizing radiation and is thought to be associated with both ER-positive and ER-negative breast cancer risks. However, since reproductive and hormonal factors may affect ER-positive breast cancer risk, the association between radon and ER-positive breast cancer risk may be masked. At the molecular level, there may still be molecular alterations associated with both ER-positive and ER-negative tumors. Our study has a number of strengths. To the best of our knowledge, this is the first prospective study to investigate radon exposure with breast cancer biology using transcriptome-wide gene expression data. We included a large number of invasive breast cancer cases. We were able to examine expression in both tumor and normal-adjacent tissues. Previous studies have suggested that the tissue surrounding tumors was morphologically and phenotypically distinct from healthy tissue, and may provide essential information for tumorigenesis [
57]. Radon represents a modifiable risk factor with a relatively feasible intervention (radon remediation).
Our study also has a few limitations. Our gene expression data was obtained from FFPE tissue blocks preserved for approximately ~ 20 years (median year of diagnosis was 1999), and RNA degradation maybe of concern. We performed pilot work and showed high correlations between
ESR1,
PGR, and
ERBB2 expression with ER, PR, and ER2 immunohistochemistry staining [
28,
29]. Our findings are unlikely to be affected by x-ray exposures from mammographic screening, since approximately 80% of women had regular screening (i.e., in each 2 year of the follow up period before diagnosis) [
58] and there was little variability by screening intensity/frequency. In our previous study, inverse probability weighting was used to create a hypothetical population in which screening was uncorrelated with all the potential risk factors of breast cancer, and results showed that small changes in effect estimates were observed for breast cancer risk factors [
58]. Radon was estimated using a county-level metric that may not actually reflect individual-level exposure and we did not have indoor radon measured individually. Household radon level may differ within a county because of variations in housing characteristics, geology, and radon remediation. Nurses, as health professionals, may be aware of radon as a carcinogen and established remediations. Our radon exposure model has been applied in previous population-based studies of lung cancer, showing expected positive associations [
59], which suggests that the model maybe a reasonable proxy for residential radon exposure. Additional research is needed to determine whether our findings can be confirmed in other cohorts, in particular for ER-negative breast cancer cases where sample size was modest. Our single gene and GSEA results need to be confirmed by future studies which include quantitative polymerase chain reactions (qPCR) of core enriched genes and protein biomarkers. Annual radon concentrations, which reflect geological, geographical and meteorological information in the study region, were all below 300 Bq/m
3. Future studies in elevated radon areas is needed to compare breast cancer characteristics. It would also be important in future work to conduct validation studies to determine the extent to which the radon exposure model is predictive of personal radon exposure.
Acknowledgements
The authors thank all participants and coordinators of the Nurses’ Health Study and the Nurses’ Health Study II for their valuable contribution, and the cancer registries in the following states for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA and WY. The authors assume full responsibility for analyses and interpretation of these data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.